{"id":37238,"date":"2020-03-05T03:00:02","date_gmt":"2020-03-05T02:00:02","guid":{"rendered":"https:\/\/www.cde.ual.es\/?p=37238"},"modified":"2021-12-11T22:46:41","modified_gmt":"2021-12-11T21:46:41","slug":"better-health-and-care-economic-growth-and-sustainable-health-systems","status":"publish","type":"post","link":"https:\/\/www.cde.ual.es\/en\/better-health-and-care-economic-growth-and-sustainable-health-systems\/","title":{"rendered":"H2020. Better Health and care, economic growth and sustainable health systems"},"content":{"rendered":"

A combination of rapid, accurate and specific diagnostics and correct treatment<\/strong> promises not only to reduce caseloads of multi-drug resistant infections, but also to limit public spending for necessary isolation and hospitalisation by early and correctly identifying the appropriate treatment.<\/p>\n

\"Enfoque<\/a><\/p>\n

In practice cost issues hamper the implementation of rapid diagnostics for ID in public health institutions, as innovative rapid diagnostics are still significantly more expensive than culture-based diagnostics. This issue and the lack of consideration of total cost of care limits the uptake of innovative rapid diagnostics in hospitals, which could result in a continued unspecific use of antimicrobials, prolonged hospitalisations and a non-patient centred provision of care.<\/p>\n

Aim<\/h3>\n

The principal aim is the implementation of timely and correct diagnostics for infectious diseases (ID) that will speed up the identification of the causative infectious disease pathogens, possible drug resistances and drug susceptibility is crucial for tailoring the antimicrobial treatment, thus ensuring appropriate antimicrobial drug use.<\/p>\n

Proposals<\/h3>\n

This topic will contribute to the EU One Health Action Plan on Antimicrobial Resistance and should specifically consider the following:<\/p>\n